Duration of trastuzumab in patients with HER2-positive metastatic breast cancer in prolonged remission

被引:13
作者
Haq, R. [1 ]
Gulasingam, P. [1 ]
机构
[1] St Michaels Hosp, 30 Bond St, Toronto, ON M5B 1W8, Canada
关键词
Metastatic breast cancer; HER2; positivity; trastuzumab; prolonged remission; COMPLETE RESPONSE; GUIDELINES;
D O I
10.3747/co.23.2743
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Outcomes in metastatic breast cancer (mBC) positive for HER2 (human epidermal growth factor receptor 2) are generally unfavourable. Trastuzumab has revolutionized the prognosis of HER2-positive mBC. Some HER2-positive mBC patients go into prolonged remission, and a few patients remain in remission even after discontinuation of trastuzumab, suggesting the possibility of a cure. In our practice, 4 HER2-positive mBC patients treated with chemotherapy and trastuzumab have remained in remission on maintenance therapy for 5 years or more. Of those 4 patients, 2 have continued in remission after discontinuation of trastuzumab for more than 1 year. The objective of the present paper was therefore to address the duration of trastuzumab therapy in HER2-positive mBC patients in prolonged remission. Methods We conducted a literature review of the duration of trastuzumab in HER2-positive mBC patients in remission. We also conducted an online survey of oncologists in Ontario to determine their treatment practices in HER2-positive mBC patients. Results The literature search found no specific evidence about the optimal duration of trastuzumab maintenance therapy in HER2-positive mBC in prolonged remission. However, retrospective studies suggest predictive markers of good prognosis in patients in complete remission taking maintenance trastuzumab. Identifying those markers could lead to more personalized treatment. Our survey of oncologists about their treatment practices in HER2-positive mBC patients revealed that 82.93% of respondents (n = 34) follow the currently available guidelines. Conclusions With the emergence of patients in prolonged remission, duration of trastuzumab in HER2-positive mBC has become an important and relevant clinical question worldwide. Collaborative efforts are needed for the further study of this topic.
引用
收藏
页码:91 / 95
页数:5
相关论文
共 22 条
[1]   Prolonged complete remission of metastatic HER2-positive breast cancer after continuous trastuzumab treatment: a case report and review of the literature [J].
Arcienega, Isabel Ihnenfeld ;
Imesch, Patrick ;
Fink, Daniel ;
Dedes, Konstantin J. .
TARGETED ONCOLOGY, 2015, 10 (02) :297-301
[2]   More than 9 years of continuous trastuzumab treatment in metastatic breast cancer without cardiac toxicity: a case report and literature review [J].
Badulescu, Florin ;
Badulescu, Adriana ;
Paul, Doru ;
Popescu, Carmen Florina ;
Florescu, Cristina .
ONCOTARGETS AND THERAPY, 2014, 7 :1911-1917
[3]  
Balasubramaniam T, 2013, PROPOSAL INCLUSION T
[4]   Long-term responders to trastuzumab among patients with HER2-positive metastatic breast cancer [J].
Barriere, J. ;
Mari, V. ;
Follana, P. ;
Largillier, R. ;
Chamorey, E. ;
Lescaut, W. ;
Flipo, B. ;
Ettore, F. ;
Raoust, I. ;
Peyrottes, I. ;
Figl, A. ;
Marcy, M. ;
Ihrai, T. ;
Courdi, A. ;
Ferrero, J. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[5]  
Beda M, 2007, TUMORI J, V93, P491
[6]  
Cancer Care Ontario (cco) Members of the Breast Cancer Disease Site Group, 2011, CANC CAR ONT CCO EV, V1-15
[7]   Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].
Cardoso, F. ;
Harbeck, N. ;
Fallowfield, L. ;
Kyriakides, S. ;
Senkus, E. .
ANNALS OF ONCOLOGY, 2012, 23 :11-19
[8]   Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review [J].
Dawood, Shaheenah ;
Broglio, Kristine ;
Buzdar, Aman U. ;
Hortobagyi, Gabriel N. ;
Giordano, Sharon H. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) :92-98
[9]   Advances in First-Line Treatment for Patients with HER-2+ Metastatic Breast Cancer [J].
De Mattos-Arruda, Leticia ;
Cortes, Javier .
ONCOLOGIST, 2012, 17 (05) :631-644
[10]  
Del Mastro L, 2012, EXPERT REV ANTICANC, V12, P1391, DOI [10.1586/era.12.107, 10.1586/ERA.12.107]